Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its 4-week and 8-week blood glucose results from its WEIGHT-A24-1 animal study (the “study”). This study will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination . The ongoing study uses diabetic, pre-conditioned Zucker rats, falling in one of three study arms, with dosing lasting 12 weeks (https://cnw.fm/1u3Rj).
Two formulations posted outstanding performance from the study as of day 56 – DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A & B). Most notably, they each posted blood sugar level reductions of 2.50%, 1.90%, and 1.53% respectively. DehydraTECH-liraglutide specifically saw a -2.08% change as of day 28 and a -2.50% change as of day 56 in what Lexaria’s management described as “extremely interesting.”
For Lexaria, these results build on the positive results from its 2023 DIAB-A22-1 animal study, which showed a 16.7% blood sugar concentration increase relative to baseline by day 56 for the obese control group that received no treatment. For the current study, each of the eight active groups of animals either experienced a smaller increase or an actual decrease in blood sugar level relative to baseline compared to the obese control group in the previous study.
The ongoing study featured eight groups. Groups A through D were administered with different DehydraTECH-CBD compositions. Groups E and F utilized reformulated Rybelsus DehydraTECH compositions, whereas groups G and G used pure glucagon-like peptide-1 (“GLP-1”) drugs semaglutide and liraglutide respectively in DehydraTECH compositions. Additional results from this study are expected soon. However, Lexaria’s management remains optimistic that it will replicate both the interim and previous results, ultimately demonstrating the superiority of its DehydraTECH technology.
The global diabetes treatment market was valued at $79.25 billion in 2023. It is projected that by 2032, it will have surpassed $153 billion in valuation, mainly influenced by the growing prevalence of the condition and the increasing demand for effective drug therapies (https://cnw.fm/WhvWz). For the longest time, treatment options have involved painful injections, which, to many, have been a source of discomfort and, to some, an outright deterrent. Lexaria looks to carve out a piece of the diabetes treatment market share by offering an oral alternative and is banking on its DehydraTECH technology to achieve that. Its previous and ongoing studies are a testament to its commitment to this goal and its pledge to creating shareholder value.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About HempWire
HempWire (“HW”) is a specialized communications platform with a focus on hemp-related news, information, and the latest developments in the hemp sector. HempWire is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, HW brings its clients unparalleled recognition and brand awareness. HW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from HempWire, text “HempWire” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.HempWire.com
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.HempWire.com/Disclaimer
HempWire
Denver, Colorado
www.HempWire.com
303.498.7722 Office
Editor@HempWire.com
HempWire is powered by IBN
Legislators in states across the country are working towards strictly regulating and/or banning intoxicating hemp…
A proposal introduced by Sen. Colleen Burton that would ban delta-8 THC hemp products is…
California recently extended a ban on intoxicating hemp products with THC that was set to…
A new poll has determined that frequent consumers of marijuana like using delivery platforms to…
The demand for plant-based proteins has increased in the last couple of years as consumer…
The CBD market in the United Kingdom has grown since the compound’s extracts were designated…